SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Maintain 5.3% Stake in Ensysce Biosciences

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, confirming their beneficial ownership of 5.3% of Ensysce Biosciences, Inc.'s common stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Ensysce Biosciences, Inc.
• The filing indicates that the Reporting Persons collectively beneficially own 86,666 shares of Ensysce Biosciences, Inc. Common Stock.
• This ownership represents 5.3% of the Issuer's outstanding Common Stock.
• The percentage is based on 1,644,728 outstanding shares of Common Stock, as reported in Ensysce Biosciences, Inc.'s Prospectus Supplement filed on March 31, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds the 86,666 shares.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, leading to their deemed beneficial ownership of the shares.
• The Reporting Persons share both voting and dispositive power over all 86,666 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company, beyond confirming an existing institutional stake.

Positives

• The continued beneficial ownership by institutional investors like Perceptive Advisors and its affiliates may signal ongoing confidence in Ensysce Biosciences, Inc.

Risks

• The document does not detail specific operational or financial risks for Ensysce Biosciences, Inc., as it is a beneficial ownership filing.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Ensysce Biosciences, Inc.'s future outlook.

Industry Context

This filing is a standard disclosure of institutional ownership in a publicly traded biotechnology company. It reflects a significant, but not controlling, stake held by a specialized life sciences investment fund.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and confirms that the stake is not held for control purposes.
• Investment Professionals: Offers insight into the holdings of a notable life sciences investment firm.

Key Dates

Keywords

Ensysce Biosciences, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals